zurück zur Startseite
Zentrale Tel.: 06221-560
Translational Lung Research Center Heidelberg

Marcus A. Mall, MD

Professor of Pediatrics
Department of Translational Pulmonolog

Translational Lung Research Center Heidelberg (TLRC)
Heidelberg University Hospital
Im Neuenheimer Feld 156
69120 Heidelberg



Phone:+49 6221 56-4502
Opens window for sending emailE-Mail


Research Interests:

  • Airway epithelial ion transport in health and disease
  • Novel animal models for cystic fibrosis and other airway diseases
  • Genotype-phenotype correlation in cystic fibrosis
  • Development of mutation specific therapies for cystic fibrosis patients


Short CV

1990-1997Medical School, University of Freiburg, Germany, and University College London School of Medicine, UK
1997Dissertation (M.D.) "summa cum laude", Institute of Physiology, University of Freiburg, Germany
1997-2000Resident, University of Freiburg Children's Hospital
2000-2003Postdoc (DFG Research Fellowship) and Research Associate, Cystic Fibrosis/Pulmonary Research and Treatment Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2003-2004Assistant Professor, Cystic Fibrosis/Pulmonary Research and Treatment Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2004-2006Fellow in Pediatric Pulmonology, Department of Pediatrics, University Hospital Heidelberg, Germany
2005-2009Group Leader of EU-funded Independent Junior Research Group "Cystic Fibrosis / Chronic Airway Disease" (Marie Curie Excellence Team)
Since 2006Faculty Member of the Hartmut-Hoffmann-Berling International Graduate School of Molecular & Cellular Biology Heidelberg (HBIGS)
Since 2006Group Leader of the Molecular Medicine Partnership Unit (MMPU) of the University of Heidelberg and the European Molecular Biology Laboratory (EMBL)
2007Assistant Professor of Pediatrics (Habilitation and venia legendi), Department of Pediatrics, Heidelberg University
2007-2017Senior Physician and Head of Cystic Fibrosis Center, Heidelberg Univerity Hospital
2009-2012Heisenberg Professorship (awarded by the German Research Foundation, DFG)
2009-2017Full Professor of Pediatrics (W3)
Head of the Division of Pediatric Pulmonology & Allergology and the Cystic Fibrosis Center, Heidelberg University
2011-2017Member of the Board of Directors, German Center for Lung Research (DZL)
2012Offer of Professorship (W3) of Pediatrics and Medical Director of General Pediatrics at the University of Freiburg, Germany - declined
2012-2017Director of the Department of Translational Pulmonology, Heidelberg University

Chairman, Translational Lung Research Center Heidelberg (TLRC)

since 2018Director, Clinic for Pediatrics, Pneumology and Immunology, Charité, Berlin



Speciality Certifications

2006Licensed Pediatrician
2008Licensed Pediatric Pulmonologist
2011Licensed for Infectious Diseases

Honors & Awards

1997Adolf-Windorfer-Prize for Cystic Fibrosis Research, German Cystic Fibrosis Foundation (Mukoviszidose e.V.)
1998Albrecht Fleckenstein Young Investigator Award, University of Freiburg
2005Professor David Shmeling Research Prize, German Society of Pediatric Gastroenterology and Nutrition
2005Johannes Wenner Prize, German Society of Pediatric Pulmonology (GPP)
2005-2009Marie Curie Excellence Grant (EU)
2009Research Award, German Society of Pulmonology (DGP)
2009Heisenberg-Professorship for Translational Pediatric Pulmonology, German Research Foundation (DFG)
2017Fellow of the European Respiratory Society (FERS)



Memberships/Committee Assignments

1998-German Society of Pediatric Pulmonology (GPP)
1998-German Society of Pedatrics and Adolescent Medicine (DGKJ)
1998- German Physiology Society (DPG)
1999-European Cystic Fibrosis Society (ECFS)
2004-German Cystic Fibrosis Association (Mukoviszidose e.V.)


Elected Member and Chairman (2010-2012) of the Reserach Council of the German Cystic Fibrosis Association
2006-American Thoracic Society (ATS)
2009-Member of the ECFS Conference Scientific Steering Committee
2010-European Respiratory Society (ERS)
2011Conference Vice President, 34th ECFS Conference, Hamburg, Germany
2011-Member of the Board of Directors, German Center for Lung Research (DZL)
2014-Elected Member of the Board of the European Cystic Fibrosis Society (ECFS)
2015-Vice-Coordinator ECFS Cystic Fibrosis Molecular & Cell Biology and Physiology Basic Science Working Group


  1. Coming Soon


MD Students

Charlotte van Bodegom

Dominik Leitz

Stephan Spahn

Jonas Herth

Robert Brock


PhD Students

Sandra Christochowitz

Matthias Hagner

Ayca Seyhan

Claudius Wagner

Pamela Millar-Büchner

Jianghui Zhe



Selected Publications

  1. Fritzsching B, Zhou-Suckow Z, Trojanek JB, Schubert SC, Schatterny J, Hirtz S, Muley T, Kahn N, Sticht C, Gunkel N, Welte T, Randell SH, Länger F, Schnabel P, Herth F, Mall MA. Hypoxic epithelial necrosis triggers neutrophilic inflammation via IL-1 receptor signaling in cystic fibrosis lung disease Am J Respir Crit Care Med 2015 Jan 21. [Epub ahead of print].
  2. Gehrig S, Duerr J, Weitnauer M, Wagner CJ, Graeber SY, Schatterny J, Hirtz S, Belaaouaj A, Dalpke AH, Schultz C, Mall MA. Lack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosis-like lung disease. Am J Respir Crit Care Med 2014;189:1082-1092.
  3. Wielputz MO, Puderbach M, Kopp-Schneider A, Stahl M, Fritzsching E, Sommerburg O, Ley S, Sumkauskaite M, Biederer J, Kauczor HU, Eichinger M, Mall MA. Magnetic resonance imaging detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease. Am J Respir Crit Care Med 2014;189:956-965.
  4. Anagnostopoulou P, Riederer B, Duerr J, Michel S, Binia A, Agrawal R, Liu X, Kalitzki K, Xiao F, Chen M, Schatterny J, Hartmann D, Thum T, Kabesch M, Soleimani M, Seidler U, Mall MA. SLC26A9-mediated chloride secretion prevents mucus obstruction in airway inflammation. J Clin Invest 2012;122:3629-3634.
  5. Cobos-Correa A, Trojanek JB, Diemer S, Mall MA*, Schultz C*. Membrane-bound FRET probe visualizes MMP12 activity in pulmonary inflammation. Nat Chem Biol 2009; 5:628-630. (*equal contribution)
  6. Zhou Z, Treis D, Schubert S, Harm M, Schatterny J, Hirtz S, Duerr J, Boucher RC, Mall MA. Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in βENaC-overexpressing mice. Am J Respir Crit Care Med 2008; 178: 1245-1256.
  7. Mall MA, Harkema JR, Trojanek JB, Treis D, Livraghi A, Schubert S, Zhou Z, Kreda SM, Tilley SL, Hudson EJ, O'Neal WK, Boucher RC. Development of chronic bronchitis and emphysema in βENaC-overexpressing mice. Am J Respir Crit Care Med 2008; 177(7): 730-42.
  8. Mall M, Grubb BR, Harkema JR, O'Neal WK, Boucher RC. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat Med 2004;10:487-493.
  9. Hirtz S, Gonska T, Seydewitz HH, Thomas J, Greiner P, Kuehr J, Brandis M, Eichler I, Rocha H, Lopes AI, Barreto C, Ramalho A, Amaral MD, Kunzelmann K, Mall M. CFTR Cl- channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. Gastroenterology 2004;127:1085-1095.
  10. Mall M, Bleich M, Greger R, Schreiber R, Kunzelmann K. The amiloride inhibitable Na+ conductance is reduced by CFTR in normal but not in cystic fibrosis airways. J Clin Invest 1998;102:15-21.
    Select languageSelect language
    Print Diese Seite per E-Mail weiterempfehlen